-
1
-
-
53249123632
-
-
IARC, Lyon, France
-
Swerdlow S.H., Campo E., Harris N.L., et al. WHO classification of tumors of haematopoietic and lymphoid tissues 2008, IARC, Lyon, France. 4th ed.
-
(2008)
WHO classification of tumors of haematopoietic and lymphoid tissues
-
-
Swerdlow, S.H.1
Campo, E.2
Harris, N.L.3
-
2
-
-
1842413105
-
The Non-Hodgkin's Lymphoma Classification Project
-
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
-
The Non-Hodgkin's Lymphoma Classification Project. Blood 1997, 89(11):3909-3918. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma.
-
(1997)
Blood
, vol.89
, Issue.11
, pp. 3909-3918
-
-
-
3
-
-
24644500086
-
Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
-
Sehn L.H., Donaldson J., Chhanabhai M., et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005, 23(22):5027-5033.
-
(2005)
J Clin Oncol
, vol.23
, Issue.22
, pp. 5027-5033
-
-
Sehn, L.H.1
Donaldson, J.2
Chhanabhai, M.3
-
4
-
-
77957965500
-
Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era
-
Gisselbrecht C., Glass B., Mounier N., et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin OncolJ Clin Oncol 2010, 28(27):4184-4190.
-
(2010)
J Clin OncolJ Clin Oncol
, vol.28
, Issue.27
, pp. 4184-4190
-
-
Gisselbrecht, C.1
Glass, B.2
Mounier, N.3
-
5
-
-
0028790440
-
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin[U+05F3]s lymphoma
-
Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin[U+05F3]s lymphoma. N Engl J Med 1995, 333(23):1540-1545.
-
(1995)
N Engl J Med
, vol.333
, Issue.23
, pp. 1540-1545
-
-
Philip, T.1
Guglielmi, C.2
Hagenbeek, A.3
-
6
-
-
77951638691
-
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma
-
Moskowitz C.H., Schoder H., Teruya-Feldstein J., et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. J Clin OncolJ Clin Oncol 2010, 28(11):1896-1903.
-
(2010)
J Clin OncolJ Clin Oncol
, vol.28
, Issue.11
, pp. 1896-1903
-
-
Moskowitz, C.H.1
Schoder, H.2
Teruya-Feldstein, J.3
-
7
-
-
33847361987
-
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
-
Sehn L.H., Berry B., Chhanabhai M., et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007, 109(5):1857-1861.
-
(2007)
Blood
, vol.109
, Issue.5
, pp. 1857-1861
-
-
Sehn, L.H.1
Berry, B.2
Chhanabhai, M.3
-
8
-
-
0027444652
-
The International Non-Hodgkin's Lymphoma Prognostic Factors Project
-
A predictive model for aggressive non-Hodgkin's lymphoma
-
The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329(14):987-994. A predictive model for aggressive non-Hodgkin's lymphoma.
-
(1993)
N Engl J Med
, vol.329
, Issue.14
, pp. 987-994
-
-
-
9
-
-
0037142053
-
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
-
Rosenwald A., Wright G., Chan W.C., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346(25):1937-1947.
-
(2002)
N Engl J Med
, vol.346
, Issue.25
, pp. 1937-1947
-
-
Rosenwald, A.1
Wright, G.2
Chan, W.C.3
-
10
-
-
0034598746
-
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
-
Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403(6769):503-511.
-
(2000)
Nature
, vol.403
, Issue.6769
, pp. 503-511
-
-
Alizadeh, A.A.1
Eisen, M.B.2
Davis, R.E.3
-
11
-
-
57149089307
-
Stromal gene signatures in large-B-cell lymphomas
-
Lenz G., Wright G., Dave S.S., et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008, 359(22):2313-2323.
-
(2008)
N Engl J Med
, vol.359
, Issue.22
, pp. 2313-2323
-
-
Lenz, G.1
Wright, G.2
Dave, S.S.3
-
12
-
-
10744228934
-
The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma
-
Savage K.J., Monti S., Kutok J.L., et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003, 102(12):3871-3879.
-
(2003)
Blood
, vol.102
, Issue.12
, pp. 3871-3879
-
-
Savage, K.J.1
Monti, S.2
Kutok, J.L.3
-
13
-
-
0043192901
-
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma
-
Wright G., Tan B., Rosenwald A., Hurt E.H., Wiestner A., Staudt L.M. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003, 100(17):9991-9996.
-
(2003)
Proc Natl Acad Sci U S A
, vol.100
, Issue.17
, pp. 9991-9996
-
-
Wright, G.1
Tan, B.2
Rosenwald, A.3
Hurt, E.H.4
Wiestner, A.5
Staudt, L.M.6
-
14
-
-
84912072610
-
Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma
-
Roschewski M., Dunleavy K., Wilson W.H. Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma. Leuk Lymphoma 2014, 55(11):2428-2437.
-
(2014)
Leuk Lymphoma
, vol.55
, Issue.11
, pp. 2428-2437
-
-
Roschewski, M.1
Dunleavy, K.2
Wilson, W.H.3
-
15
-
-
84885183435
-
Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma
-
Puvvada S., Kendrick S., Rimsza L. Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma. Cancer Genet 2013, 206(7-8):257-265.
-
(2013)
Cancer Genet
, vol.206
, Issue.7-8
, pp. 257-265
-
-
Puvvada, S.1
Kendrick, S.2
Rimsza, L.3
-
16
-
-
84871578597
-
Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?
-
Barton S., Hawkes E.A., Wotherspoon A., Cunningham D. Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?. Oncologist 2012, 17(12):1562-1573.
-
(2012)
Oncologist
, vol.17
, Issue.12
, pp. 1562-1573
-
-
Barton, S.1
Hawkes, E.A.2
Wotherspoon, A.3
Cunningham, D.4
-
17
-
-
84896403797
-
Accelerated therapeutic progress in diffuse large B cell lymphoma
-
Cai Q., Westin J., Fu K., et al. Accelerated therapeutic progress in diffuse large B cell lymphoma. Ann Hematol 2014, 93(4):541-556.
-
(2014)
Ann Hematol
, vol.93
, Issue.4
, pp. 541-556
-
-
Cai, Q.1
Westin, J.2
Fu, K.3
-
18
-
-
84891001835
-
Diffuse large B-cell lymphoma-treatment approaches in the molecular era
-
Roschewski M., Staudt L.M., Wilson W.H. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol 2014, 11(1):12-23.
-
(2014)
Nat Rev Clin Oncol
, vol.11
, Issue.1
, pp. 12-23
-
-
Roschewski, M.1
Staudt, L.M.2
Wilson, W.H.3
-
19
-
-
66649127621
-
Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma
-
Compagno M., Lim W.K., Grunn A., et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009, 459(7247):717-721.
-
(2009)
Nature
, vol.459
, Issue.7247
, pp. 717-721
-
-
Compagno, M.1
Lim, W.K.2
Grunn, A.3
-
20
-
-
0035905313
-
Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells
-
Davis R.E., Brown K.D., Siebenlist U., Staudt L.M. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001, 194(12):1861-1874.
-
(2001)
J Exp Med
, vol.194
, Issue.12
, pp. 1861-1874
-
-
Davis, R.E.1
Brown, K.D.2
Siebenlist, U.3
Staudt, L.M.4
-
21
-
-
75749124332
-
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
-
Morin R.D., Johnson N.A., Severson T.M., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010, 42(2):181-185.
-
(2010)
Nat Genet
, vol.42
, Issue.2
, pp. 181-185
-
-
Morin, R.D.1
Johnson, N.A.2
Severson, T.M.3
-
22
-
-
80052029516
-
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
-
Morin R.D., Mendez-Lago M., Mungall A.J., et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 476(7360):298-303.
-
(2011)
Nature
, vol.476
, Issue.7360
, pp. 298-303
-
-
Morin, R.D.1
Mendez-Lago, M.2
Mungall, A.J.3
-
23
-
-
79952430906
-
Inactivating mutations of acetyltransferase genes in B-cell lymphoma
-
Pasqualucci L., Dominguez-Sola D., Chiarenza A., et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011, 471(7337):189-195.
-
(2011)
Nature
, vol.471
, Issue.7337
, pp. 189-195
-
-
Pasqualucci, L.1
Dominguez-Sola, D.2
Chiarenza, A.3
-
24
-
-
3042594986
-
BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma
-
Iqbal J., Sanger W.G., Horsman D.E., et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol 2004, 165(1):159-166.
-
(2004)
Am J Pathol
, vol.165
, Issue.1
, pp. 159-166
-
-
Iqbal, J.1
Sanger, W.G.2
Horsman, D.E.3
-
25
-
-
73849145729
-
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
-
Davis R.E., Ngo V.N., Lenz G., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463(7277):88-92.
-
(2010)
Nature
, vol.463
, Issue.7277
, pp. 88-92
-
-
Davis, R.E.1
Ngo, V.N.2
Lenz, G.3
-
26
-
-
70350304558
-
PI3 kinase signals BCR-dependent mature B cell survival
-
Srinivasan L., Sasaki Y., Calado D.P., et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009, 139(3):573-586.
-
(2009)
Cell
, vol.139
, Issue.3
, pp. 573-586
-
-
Srinivasan, L.1
Sasaki, Y.2
Calado, D.P.3
-
27
-
-
43549097394
-
Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma
-
Lam L.T., Wright G., Davis R.E., et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 2008, 111(7):3701-3713.
-
(2008)
Blood
, vol.111
, Issue.7
, pp. 3701-3713
-
-
Lam, L.T.1
Wright, G.2
Davis, R.E.3
-
28
-
-
84878969076
-
SYK inhibition modulates distinct PI3K/AKT-dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas
-
Chen L., Monti S., Juszczynski P., et al. SYK inhibition modulates distinct PI3K/AKT-dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell 2013, 23(6):826-838.
-
(2013)
Cancer Cell
, vol.23
, Issue.6
, pp. 826-838
-
-
Chen, L.1
Monti, S.2
Juszczynski, P.3
-
29
-
-
83455225523
-
SYK inhibition and response prediction in diffuse large B-cell lymphoma
-
Cheng S., Coffey G., Zhang X.H., et al. SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood 2011, 118(24):6342-6352.
-
(2011)
Blood
, vol.118
, Issue.24
, pp. 6342-6352
-
-
Cheng, S.1
Coffey, G.2
Zhang, X.H.3
-
30
-
-
77951002653
-
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
-
Friedberg J.W., Sharman J., Sweetenham J., et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115(13):2578-2585.
-
(2010)
Blood
, vol.115
, Issue.13
, pp. 2578-2585
-
-
Friedberg, J.W.1
Sharman, J.2
Sweetenham, J.3
-
31
-
-
38049084406
-
Discovery of selective irreversible inhibitors for Bruton[U+05F3]s tyrosine kinase
-
Pan Z., Scheerens H., Li S.J., et al. Discovery of selective irreversible inhibitors for Bruton[U+05F3]s tyrosine kinase. Chem Med Chem 2007, 2(1):58-61.
-
(2007)
Chem Med Chem
, vol.2
, Issue.1
, pp. 58-61
-
-
Pan, Z.1
Scheerens, H.2
Li, S.J.3
-
32
-
-
84883160397
-
Ibrutinib and novel BTK inhibitors in clinical development
-
Akinleye A., Chen Y., Mukhi N., Song Y., Liu D. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol 2013, 6:59.
-
(2013)
J Hematol Oncol
, vol.6
, pp. 59
-
-
Akinleye, A.1
Chen, Y.2
Mukhi, N.3
Song, Y.4
Liu, D.5
-
33
-
-
84886386342
-
Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas
-
Aalipour A., Advani R.H. Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas. Br J Haematol 2013, 163(4):436-443.
-
(2013)
Br J Haematol
, vol.163
, Issue.4
, pp. 436-443
-
-
Aalipour, A.1
Advani, R.H.2
-
34
-
-
77955625479
-
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
-
Honigberg L.A., Smith A.M., Sirisawad M., et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010, 107(29):13075-13080.
-
(2010)
Proc Natl Acad Sci U S A
, vol.107
, Issue.29
, pp. 13075-13080
-
-
Honigberg, L.A.1
Smith, A.M.2
Sirisawad, M.3
-
35
-
-
84871806385
-
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies
-
Advani R.H., Buggy J.J., Sharman J.P., et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013, 31(1):88-94.
-
(2013)
J Clin Oncol
, vol.31
, Issue.1
, pp. 88-94
-
-
Advani, R.H.1
Buggy, J.J.2
Sharman, J.P.3
-
36
-
-
84874585216
-
The bruton[U+05F3]s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the abc subtype of relapsed/refractory de novo diffuse large b-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study
-
Wilson W., Gerecitano J., Goy A., De Vos S. The bruton[U+05F3]s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the abc subtype of relapsed/refractory de novo diffuse large b-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Blood 2012, 120(21):a686.
-
(2012)
Blood
, vol.120
, Issue.21
, pp. a686
-
-
Wilson, W.1
Gerecitano, J.2
Goy, A.3
De Vos, S.4
-
37
-
-
84904999787
-
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study
-
Younes A., Thieblemont C., Morschhauser F., et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol 2014, 15(9):1019-1026.
-
(2014)
Lancet Oncol
, vol.15
, Issue.9
, pp. 1019-1026
-
-
Younes, A.1
Thieblemont, C.2
Morschhauser, F.3
-
38
-
-
84925239641
-
A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL)
-
(suppl; abstr TPS8615).
-
Younes A.Z.P., Sehn L.H., Johnson P.W., et al. A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL). J Clin OncolJ Clin Oncol 2014, 32(5s). (suppl; abstr TPS8615).
-
(2014)
J Clin OncolJ Clin Oncol
, vol.32
, Issue.5 S
-
-
Younes, A.Z.P.1
Sehn, L.H.2
Johnson, P.W.3
-
39
-
-
34249075706
-
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma
-
Robertson M.J., Kahl B.S., Vose J.M., et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007, 25(13):1741-1746.
-
(2007)
J Clin Oncol
, vol.25
, Issue.13
, pp. 1741-1746
-
-
Robertson, M.J.1
Kahl, B.S.2
Vose, J.M.3
-
40
-
-
84898401507
-
A phase III study of enzastaurin in patients with high-risk diffuse large B cell lymphoma following response to primary treatment: the Prelude trial
-
Crump M.L.S., Fayad L.E., Lee J., et al. A phase III study of enzastaurin in patients with high-risk diffuse large B cell lymphoma following response to primary treatment: the Prelude trial. Blood 2013, 122(21):a623.
-
(2013)
Blood
, vol.122
, Issue.21
, pp. a623
-
-
Crump, M.L.S.1
Fayad, L.E.2
Lee, J.3
-
41
-
-
84857640749
-
Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis
-
(abstr 8016).
-
Hainsworth JD AE, McCleod M., Fayad L., Hamid O., Davis L., Lin B.K. Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis. J Clin OncolJ Clin Oncol 2011, 29(suppl). (abstr 8016).
-
(2011)
J Clin OncolJ Clin Oncol
, vol.29
-
-
Hainsworth, J.D.A.E.1
McCleod, M.2
Fayad, L.3
Hamid, O.4
Davis, L.5
Lin, B.K.6
-
42
-
-
79953323846
-
Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas
-
Naylor T.L., Tang H., Ratsch B.A., et al. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res 2011, 71(7):2643-2653.
-
(2011)
Cancer Res
, vol.71
, Issue.7
, pp. 2643-2653
-
-
Naylor, T.L.1
Tang, H.2
Ratsch, B.A.3
-
43
-
-
0034084163
-
Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity
-
Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000, 18:621-663.
-
(2000)
Annu Rev Immunol
, vol.18
, pp. 621-663
-
-
Karin, M.1
Ben-Neriah, Y.2
-
44
-
-
84858113865
-
No one can whistle a symphony alone - how different ubiquitin linkages cooperate to orchestrate NF-kappaB activity
-
Schmukle A.C., Walczak H. No one can whistle a symphony alone - how different ubiquitin linkages cooperate to orchestrate NF-kappaB activity. J Cell Sci 2012, 125(Pt 3):549-559.
-
(2012)
J Cell Sci
, vol.125
, pp. 549-559
-
-
Schmukle, A.C.1
Walczak, H.2
-
45
-
-
84904283182
-
Bortezomib inhibits proteasomal degradation of IkappaBalpha and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma
-
Bu R., Hussain A.R., Al-Obaisi K.A., Ahmed M., Uddin S., Al-Kuraya K.S. Bortezomib inhibits proteasomal degradation of IkappaBalpha and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma. Leuk Lymphoma 2014, 55(2):415-424.
-
(2014)
Leuk Lymphoma
, vol.55
, Issue.2
, pp. 415-424
-
-
Bu, R.1
Hussain, A.R.2
Al-Obaisi, K.A.3
Ahmed, M.4
Uddin, S.5
Al-Kuraya, K.S.6
-
46
-
-
19944428834
-
Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling
-
Lam L.T., Davis R.E., Pierce J., et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005, 11(1):28-40.
-
(2005)
Clin Cancer Res
, vol.11
, Issue.1
, pp. 28-40
-
-
Lam, L.T.1
Davis, R.E.2
Pierce, J.3
-
47
-
-
67650398258
-
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
-
Dunleavy K., Pittaluga S., Czuczman M.S., et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009, 113(24):6069-6076.
-
(2009)
Blood
, vol.113
, Issue.24
, pp. 6069-6076
-
-
Dunleavy, K.1
Pittaluga, S.2
Czuczman, M.S.3
-
48
-
-
84889084747
-
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study
-
Zinzani P.L., Pellegrini C., Merla E., et al. Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study. Hematol Oncol 2013, 31(4):179-182.
-
(2013)
Hematol Oncol
, vol.31
, Issue.4
, pp. 179-182
-
-
Zinzani, P.L.1
Pellegrini, C.2
Merla, E.3
-
49
-
-
79952154013
-
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma
-
Ruan J., Martin P., Furman R.R., et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011, 29(6):690-697.
-
(2011)
J Clin Oncol
, vol.29
, Issue.6
, pp. 690-697
-
-
Ruan, J.1
Martin, P.2
Furman, R.R.3
-
50
-
-
77953937449
-
The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo
-
Dasmahapatra G., Lembersky D., Kramer L., et al. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 2010, 115(22):4478-4487.
-
(2010)
Blood
, vol.115
, Issue.22
, pp. 4478-4487
-
-
Dasmahapatra, G.1
Lembersky, D.2
Kramer, L.3
-
51
-
-
84890992528
-
The irreversible proteasome inhibitor carfilzomib interacts synergistically with the selective HDAC6 inhibitor ACY1215 in ABC- and GC-DLBCL and mantle cell lymphoma sensitive or resistant to bortezomib
-
Dasmahapatra G.P.H., Al-Khafaji J.T., Fisher R.I., Friedberg J.W., Grant S. The irreversible proteasome inhibitor carfilzomib interacts synergistically with the selective HDAC6 inhibitor ACY1215 in ABC- and GC-DLBCL and mantle cell lymphoma sensitive or resistant to bortezomib. Blood 2012, 120(21):2765.
-
(2012)
Blood
, vol.120
, Issue.21
, pp. 2765
-
-
Dasmahapatra, G.P.H.1
Al-Khafaji, J.T.2
Fisher, R.I.3
Friedberg, J.W.4
Grant, S.5
-
52
-
-
84889004860
-
Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients
-
Zinzani P.L., Pellegrini C., Derenzini E., Argnani L., Pileri S. Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. Hematol Oncol 2013, 31(4):223-224.
-
(2013)
Hematol Oncol
, vol.31
, Issue.4
, pp. 223-224
-
-
Zinzani, P.L.1
Pellegrini, C.2
Derenzini, E.3
Argnani, L.4
Pileri, S.5
-
53
-
-
79959722615
-
An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin[U+05F3]s lymphoma
-
Witzig T.E., Vose J.M., Zinzani P.L., et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin[U+05F3]s lymphoma. Ann Oncol 2011, 22(7):1622-1627.
-
(2011)
Ann Oncol
, vol.22
, Issue.7
, pp. 1622-1627
-
-
Witzig, T.E.1
Vose, J.M.2
Zinzani, P.L.3
-
54
-
-
54449095901
-
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin[U+05F3]s lymphoma
-
Wiernik P.H., Lossos I.S., Tuscano J.M., et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin[U+05F3]s lymphoma. J Clin OncolJ Clin Oncol 2008, 26(30):4952-4957.
-
(2008)
J Clin OncolJ Clin Oncol
, vol.26
, Issue.30
, pp. 4952-4957
-
-
Wiernik, P.H.1
Lossos, I.S.2
Tuscano, J.M.3
-
55
-
-
84923922267
-
Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study
-
Nowakowski G.S., LaPlant B., Macon W.R., et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin OncolJ Clin Oncol Aug 18 2014.
-
(2014)
J Clin OncolJ Clin Oncol
-
-
Nowakowski, G.S.1
LaPlant, B.2
Macon, W.R.3
-
56
-
-
84873571469
-
Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma
-
Tilly H., Morschhauser F., Salles G., et al. Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Leukemia 2013, 27(1):252-255.
-
(2013)
Leukemia
, vol.27
, Issue.1
, pp. 252-255
-
-
Tilly, H.1
Morschhauser, F.2
Salles, G.3
-
57
-
-
84901391325
-
Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial
-
Vitolo U., Chiappella A., Franceschetti S., et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol 2014, 15(7):730-737.
-
(2014)
Lancet Oncol
, vol.15
, Issue.7
, pp. 730-737
-
-
Vitolo, U.1
Chiappella, A.2
Franceschetti, S.3
-
58
-
-
79960220394
-
Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response
-
Lopez-Girona A., Heintel D., Zhang L.H., et al. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 2011, 154(3):325-336.
-
(2011)
Br J Haematol
, vol.154
, Issue.3
, pp. 325-336
-
-
Lopez-Girona, A.1
Heintel, D.2
Zhang, L.H.3
-
59
-
-
69949096727
-
Mechanism of action of lenalidomide in hematological malignancies
-
Kotla V., Goel S., Nischal S., et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009, 2:36.
-
(2009)
J Hematol Oncol
, vol.2
, pp. 36
-
-
Kotla, V.1
Goel, S.2
Nischal, S.3
-
60
-
-
84873076585
-
Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression
-
Zhang L.H., Kosek J., Wang M., Heise C., Schafer P.H., Chopra R. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol 2013, 160(4):487-502.
-
(2013)
Br J Haematol
, vol.160
, Issue.4
, pp. 487-502
-
-
Zhang, L.H.1
Kosek, J.2
Wang, M.3
Heise, C.4
Schafer, P.H.5
Chopra, R.6
-
61
-
-
84862152044
-
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma
-
Yang Y., Shaffer A.L., Emre N.C., et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012, 21(6):723-737.
-
(2012)
Cancer Cell
, vol.21
, Issue.6
, pp. 723-737
-
-
Yang, Y.1
Shaffer, A.L.2
Emre, N.C.3
-
62
-
-
84881664038
-
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation
-
Vose J.M., Habermann T.M., Czuczman M.S., et al. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. Br J Haematol 2013, 162(5):639-647.
-
(2013)
Br J Haematol
, vol.162
, Issue.5
, pp. 639-647
-
-
Vose, J.M.1
Habermann, T.M.2
Czuczman, M.S.3
-
63
-
-
80053502780
-
Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype
-
Hernandez-Ilizaliturri F.J., Deeb G., Zinzani P.L., et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011, 117(22):5058-5066.
-
(2011)
Cancer
, vol.117
, Issue.22
, pp. 5058-5066
-
-
Hernandez-Ilizaliturri, F.J.1
Deeb, G.2
Zinzani, P.L.3
-
64
-
-
84887011781
-
Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi
-
Chiappella A., Tucci A., Castellino A., et al. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. Haematologica 2013, 98(11):1732-1738.
-
(2013)
Haematologica
, vol.98
, Issue.11
, pp. 1732-1738
-
-
Chiappella, A.1
Tucci, A.2
Castellino, A.3
-
65
-
-
84874650275
-
Development of PI3K inhibitors: lessons learned from early clinical trials
-
Rodon J., Dienstmann R., Serra V., Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 2013, 10(3):143-153.
-
(2013)
Nat Rev Clin Oncol
, vol.10
, Issue.3
, pp. 143-153
-
-
Rodon, J.1
Dienstmann, R.2
Serra, V.3
Tabernero, J.4
-
66
-
-
51649111684
-
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
-
Lenz G., Wright G.W., Emre N.C., et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008, 105(36):13520-13525.
-
(2008)
Proc Natl Acad Sci U S A
, vol.105
, Issue.36
, pp. 13520-13525
-
-
Lenz, G.1
Wright, G.W.2
Emre, N.C.3
-
67
-
-
84880672380
-
PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma
-
Pfeifer M., Grau M., Lenze D., et al. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 2013, 110(30):12420-12425.
-
(2013)
Proc Natl Acad Sci U S A
, vol.110
, Issue.30
, pp. 12420-12425
-
-
Pfeifer, M.1
Grau, M.2
Lenze, D.3
-
68
-
-
79953655788
-
CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 delta, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia
-
Furman R.R., Byrd J.C., Brown J.R., et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 delta, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010, 116(21):31.
-
(2010)
Blood
, vol.116
, Issue.21
, pp. 31
-
-
Furman, R.R.1
Byrd, J.C.2
Brown, J.R.3
-
69
-
-
79958784935
-
Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 delta, in patients with relapsed or refractory non-Hodgkin lymphoma
-
Kahl B., Byrd J.C., Flinn I.W., et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 delta, in patients with relapsed or refractory non-Hodgkin lymphoma. Blood 2010, 116(21):741.
-
(2010)
Blood
, vol.116
, Issue.21
, pp. 741
-
-
Kahl, B.1
Byrd, J.C.2
Flinn, I.W.3
-
70
-
-
84893326301
-
Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-delta,gamma in patients with relapsed/refractory lymphoma
-
Horwitz S.M., Flinn I., Patel M.R., et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-delta,gamma in patients with relapsed/refractory lymphoma. J Clin Oncol 2013, 31(15).
-
(2013)
J Clin Oncol
, vol.31
, Issue.15
-
-
Horwitz, S.M.1
Flinn, I.2
Patel, M.R.3
-
71
-
-
84906812169
-
Preliminary results of a phase II study of single agent bay 80-6946, a novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma
-
Dreyling M., Morschhauser F., Bron D., et al. Preliminary results of a phase II study of single agent bay 80-6946, a novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma. Blood 2013, 122(21).
-
(2013)
Blood
, vol.122
, Issue.21
-
-
Dreyling, M.1
Morschhauser, F.2
Bron, D.3
-
72
-
-
79751526328
-
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
-
Witzig T.E., Reeder C.B., LaPlant B.R., et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011, 25(2):341-347.
-
(2011)
Leukemia
, vol.25
, Issue.2
, pp. 341-347
-
-
Witzig, T.E.1
Reeder, C.B.2
LaPlant, B.R.3
-
73
-
-
78149239933
-
Temsirolimus has activity in non-mantle cell non-Hodgkin[U+05F3]s lymphoma subtypes: The University of Chicago phase II consortium
-
Smith S.M., van Besien K., Karrison T., et al. Temsirolimus has activity in non-mantle cell non-Hodgkin[U+05F3]s lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol 2010, 28(31):4740-4746.
-
(2010)
J Clin Oncol
, vol.28
, Issue.31
, pp. 4740-4746
-
-
Smith, S.M.1
van Besien, K.2
Karrison, T.3
-
74
-
-
84875651324
-
Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma
-
Barnes J.A., Jacobsen E., Feng Y., et al. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica 2013, 98(4):615-619.
-
(2013)
Haematologica
, vol.98
, Issue.4
, pp. 615-619
-
-
Barnes, J.A.1
Jacobsen, E.2
Feng, Y.3
-
75
-
-
84902254046
-
The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients
-
Davids M.S., Seymour J.F., Gerecitano J.F., et al. The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients. Blood 2013, 122:21.
-
(2013)
Blood
, vol.122
, pp. 21
-
-
Davids, M.S.1
Seymour, J.F.2
Gerecitano, J.F.3
-
76
-
-
84873540049
-
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
-
Souers A.J., Leverson J.D., Boghaert E.R., et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013, 19(2):202-208.
-
(2013)
Nat Med
, vol.19
, Issue.2
, pp. 202-208
-
-
Souers, A.J.1
Leverson, J.D.2
Boghaert, E.R.3
-
77
-
-
84885421557
-
Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL)
-
Davids M.S., Seymour J.F., Gerecitano J.F., et al. Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). J Clin Oncol 2013, 31:15.
-
(2013)
J Clin Oncol
, vol.31
, pp. 15
-
-
Davids, M.S.1
Seymour, J.F.2
Gerecitano, J.F.3
-
78
-
-
84910091007
-
Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses
-
(suppl; abstr 8522)
-
Davids M.S., Seymour J.F., Gerecitano J.F., et al. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. J Clin OncolJ Clin Oncol 2014, 32(5S). (suppl; abstr 8522).
-
(2014)
J Clin OncolJ Clin Oncol
, vol.32
, Issue.5 S
-
-
Davids, M.S.1
Seymour, J.F.2
Gerecitano, J.F.3
-
79
-
-
38949165127
-
Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas
-
Ding B.B., Yu J.J., Yu R.Y., et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008, 111(3):1515-1523.
-
(2008)
Blood
, vol.111
, Issue.3
, pp. 1515-1523
-
-
Ding, B.B.1
Yu, J.J.2
Yu, R.Y.3
-
80
-
-
79955485953
-
STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma
-
Scuto A., Kujawski M., Kowolik C., et al. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res 2011, 71(9):3182-3188.
-
(2011)
Cancer Res
, vol.71
, Issue.9
, pp. 3182-3188
-
-
Scuto, A.1
Kujawski, M.2
Kowolik, C.3
-
81
-
-
84869401524
-
Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes
-
Younes A., Romaguera J., Fanale M., et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin OncolJ Clin Oncol 2012, 30(33):4161-4167.
-
(2012)
J Clin OncolJ Clin Oncol
, vol.30
, Issue.33
, pp. 4161-4167
-
-
Younes, A.1
Romaguera, J.2
Fanale, M.3
-
82
-
-
84877815031
-
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation
-
Beguelin W., Popovic R., Teater M., et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013, 23(5):677-692.
-
(2013)
Cancer Cell
, vol.23
, Issue.5
, pp. 677-692
-
-
Beguelin, W.1
Popovic, R.2
Teater, M.3
-
83
-
-
78650062951
-
EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis
-
Velichutina I., Shaknovich R., Geng H., et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 2010, 116(24):5247-5255.
-
(2010)
Blood
, vol.116
, Issue.24
, pp. 5247-5255
-
-
Velichutina, I.1
Shaknovich, R.2
Geng, H.3
-
84
-
-
84871841675
-
Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
-
Qi W., Chan H., Teng L., et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A 2012, 109(52):21360-21365.
-
(2012)
Proc Natl Acad Sci U S A
, vol.109
, Issue.52
, pp. 21360-21365
-
-
Qi, W.1
Chan, H.2
Teng, L.3
-
85
-
-
84870573126
-
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
-
McCabe M.T., Ott H.M., Ganji G., et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492(7427):108-112.
-
(2012)
Nature
, vol.492
, Issue.7427
, pp. 108-112
-
-
McCabe, M.T.1
Ott, H.M.2
Ganji, G.3
-
86
-
-
80053651202
-
Targeting MYC dependence in cancer by inhibiting BET bromodomains
-
Mertz J.A., Conery A.R., Bryant B.M., et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 2011, 108(40):16669-16674.
-
(2011)
Proc Natl Acad Sci U S A
, vol.108
, Issue.40
, pp. 16669-16674
-
-
Mertz, J.A.1
Conery, A.R.2
Bryant, B.M.3
-
87
-
-
80052955256
-
BET bromodomain inhibition as a therapeutic strategy to target c-Myc
-
Delmore J.E., Issa G.C., Lemieux M.E., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146(6):904-917.
-
(2011)
Cell
, vol.146
, Issue.6
, pp. 904-917
-
-
Delmore, J.E.1
Issa, G.C.2
Lemieux, M.E.3
-
88
-
-
84942516634
-
BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies
-
Herait P., Berthon C., Thieblemont C., et al. BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies. Am Assoc Cancer Res 2014.
-
(2014)
Am Assoc Cancer Res
-
-
Herait, P.1
Berthon, C.2
Thieblemont, C.3
-
89
-
-
84879866976
-
PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies
-
Chen B.J., Chapuy B., Ouyang J., et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013, 19(13):3462-3473.
-
(2013)
Clin Cancer Res
, vol.19
, Issue.13
, pp. 3462-3473
-
-
Chen, B.J.1
Chapuy, B.2
Ouyang, J.3
-
90
-
-
84890096527
-
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial
-
Armand P., Nagler A., Weller E.A., et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 2013, 31(33):4199206.
-
(2013)
J Clin Oncol
, vol.31
, Issue.33
, pp. 4199206
-
-
Armand, P.1
Nagler, A.2
Weller, E.A.3
-
91
-
-
84907293786
-
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor
-
Kochenderfer J.N., Dudley M.E., Kassim S.H., et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2014.
-
(2014)
J Clin Oncol
-
-
Kochenderfer, J.N.1
Dudley, M.E.2
Kassim, S.H.3
-
92
-
-
84963534762
-
Effective treatment of chemotherapy-refractory diffuse large B-cell lymphoma with autologous t cells genetically-engineered to express an anti-CD19 chimeric antigen receptor
-
Kochenderfer J.N., Dudley M.E., Kassim S.H., et al. Effective treatment of chemotherapy-refractory diffuse large B-cell lymphoma with autologous t cells genetically-engineered to express an anti-CD19 chimeric antigen receptor. Blood 2013, 122:21.
-
(2013)
Blood
, vol.122
, pp. 21
-
-
Kochenderfer, J.N.1
Dudley, M.E.2
Kassim, S.H.3
-
93
-
-
84910006341
-
Precision therapy for lymphoma-current state and future directions
-
Intlekofer A.M., Younes A. Precision therapy for lymphoma-current state and future directions. Nat Rev Clin Oncol 2014.
-
(2014)
Nat Rev Clin Oncol
-
-
Intlekofer, A.M.1
Younes, A.2
-
94
-
-
84899448200
-
Diffuse large B-cell lymphoma: changing treatment paradigms
-
Batlevi C.L., Younes A. Diffuse large B-cell lymphoma: changing treatment paradigms. Oncology 2014, 28(4):339-341.
-
(2014)
Oncology
, vol.28
, Issue.4
, pp. 339-341
-
-
Batlevi, C.L.1
Younes, A.2
-
95
-
-
41149136296
-
Oncogenic CARD11 mutations in human diffuse large B cell lymphoma
-
Lenz G., Davis R.E., Ngo V.N., et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008, 319(5870):1676-1679.
-
(2008)
Science
, vol.319
, Issue.5870
, pp. 1676-1679
-
-
Lenz, G.1
Davis, R.E.2
Ngo, V.N.3
-
96
-
-
0026722655
-
Cooperative interaction between c-myc and bcl-2 proto-oncogenes
-
Fanidi A., Harrington E.A., Evan G.I. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 1992, 359(6395):554-556.
-
(1992)
Nature
, vol.359
, Issue.6395
, pp. 554-556
-
-
Fanidi, A.1
Harrington, E.A.2
Evan, G.I.3
-
97
-
-
0026688162
-
Apoptotic cell death induced by c-myc is inhibited by bcl-2
-
Bissonnette R.P., Echeverri F., Mahboubi A., Green D.R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992, 359(6395):552-554.
-
(1992)
Nature
, vol.359
, Issue.6395
, pp. 552-554
-
-
Bissonnette, R.P.1
Echeverri, F.2
Mahboubi, A.3
Green, D.R.4
-
98
-
-
84877929526
-
ABT-199 a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia
-
Vandenberg C.J., Cory S. ABT-199 a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 2013, 121(12):2285-2288.
-
(2013)
Blood
, vol.121
, Issue.12
, pp. 2285-2288
-
-
Vandenberg, C.J.1
Cory, S.2
-
99
-
-
84865114403
-
Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis
-
Sander S., Calado D.P., Srinivasan L., et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 2012, 22(2):167-179.
-
(2012)
Cancer Cell
, vol.22
, Issue.2
, pp. 167-179
-
-
Sander, S.1
Calado, D.P.2
Srinivasan, L.3
-
100
-
-
77951566551
-
NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma
-
Han S.S., Yun H., Son D.J., et al. NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma. Molec Cancer 2010, 9:97.
-
(2010)
Molec Cancer
, vol.9
, pp. 97
-
-
Han, S.S.1
Yun, H.2
Son, D.J.3
-
101
-
-
84879437606
-
Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas
-
Shortt J., Martin B.P., Newbold A., et al. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood 2013, 121(15):2964-2974.
-
(2013)
Blood
, vol.121
, Issue.15
, pp. 2964-2974
-
-
Shortt, J.1
Martin, B.P.2
Newbold, A.3
-
102
-
-
79960341257
-
Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin[U+05F3]s lymphoma
-
Civallero M., Cosenza M., Bari A., Sacchi S. Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin[U+05F3]s lymphoma. Expert Opin Inv Drug 2011, 20(8):1029-1031.
-
(2011)
Expert Opin Inv Drug
, vol.20
, Issue.8
, pp. 1029-1031
-
-
Civallero, M.1
Cosenza, M.2
Bari, A.3
Sacchi, S.4
-
103
-
-
84871573163
-
Combination of NVP-BEZ235 and enzastaurin on B-cell lymphoma cell lines: an effective therapeutic strategy
-
Civallero M., Cosenza M., Pozzi S., Sacchi S. Combination of NVP-BEZ235 and enzastaurin on B-cell lymphoma cell lines: an effective therapeutic strategy. Blood 2011, 118(21):1170.
-
(2011)
Blood
, vol.118
, Issue.21
, pp. 1170
-
-
Civallero, M.1
Cosenza, M.2
Pozzi, S.3
Sacchi, S.4
-
104
-
-
84862727403
-
Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo
-
Dasmahapatra G., Lembersky D., Son M.P., et al. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo. Mol Cancer Ther 2012, 11(5):1122-1132.
-
(2012)
Mol Cancer Ther
, vol.11
, Issue.5
, pp. 1122-1132
-
-
Dasmahapatra, G.1
Lembersky, D.2
Son, M.P.3
-
105
-
-
84905641032
-
Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors
-
Ceribelli M., Kelly P.N., Shaffer A.L., et al. Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci U S A 2014, 111(31):11365-11370.
-
(2014)
Proc Natl Acad Sci U S A
, vol.111
, Issue.31
, pp. 11365-11370
-
-
Ceribelli, M.1
Kelly, P.N.2
Shaffer, A.L.3
-
106
-
-
84893825160
-
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells
-
Mathews Griner L.A., Guha R., Shinn P., et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A 2014, 111(6):2349-2354.
-
(2014)
Proc Natl Acad Sci U S A
, vol.111
, Issue.6
, pp. 2349-2354
-
-
Mathews Griner, L.A.1
Guha, R.2
Shinn, P.3
-
107
-
-
84890606231
-
Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma
-
Oki Y., Buglio D., Fanale M., et al. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res 2013, 19(24):6882-6890.
-
(2013)
Clin Cancer Res
, vol.19
, Issue.24
, pp. 6882-6890
-
-
Oki, Y.1
Buglio, D.2
Fanale, M.3
-
108
-
-
84859770736
-
Phase 1 trial of sorafenib and everolimus in patients with lymphoma or multiple myeloma
-
Kumar S., Porrata L.F., Ansell S.M., et al. Phase 1 trial of sorafenib and everolimus in patients with lymphoma or multiple myeloma. Blood 2010, 116(21):1155-1156.
-
(2010)
Blood
, vol.116
, Issue.21
, pp. 1155-1156
-
-
Kumar, S.1
Porrata, L.F.2
Ansell, S.M.3
|